{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:03:23Z","timestamp":1791407003109,"version":"4.3.3"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.amjcard.2025.08.028","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T16:20:39Z","timestamp":1755620439000},"page":"130-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Predictors of Sodium Glucose Co-Transporter-2 Inhibitor Utilization in Elderly Heart Failure Patients: A Real-World Population-Level Dataset Analysis"],"prefix":"10.1016","volume":"256","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1821-6622","authenticated-orcid":false,"given":"Zubair","family":"Bashir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritika","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wissam","family":"Khalife","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Jneid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Chatila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiham","family":"Albaeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.amjcard.2025.08.028_bib0001","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jacc.2019.06.053","article-title":"Cardiovascular aging and heart failure: JACC review topic of the week","volume":"74","author":"Triposkiadis","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.amjcard.2025.08.028_bib0002","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jchf.2017.12.006","article-title":"Innovation in heart failure treatment: life expectancy, disability, and health disparities","volume":"6","author":"Van Nuys","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10.1016\/j.amjcard.2025.08.028_bib0003","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cardfail.2024.07.001","article-title":"HF STATS 2024: heart failure epidemiology and outcomes statistics an updated 2024 report from the heart failure society of America","volume":"31","author":"Bozkurt","year":"2025","journal-title":"J Card Fail"},{"issue":"1","key":"10.1016\/j.amjcard.2025.08.028_bib0004","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001279","article-title":"Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012-2018","volume":"8","author":"Engler","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"4","key":"10.1016\/j.amjcard.2025.08.028_bib0005","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2666-7568(23)00039-9","article-title":"SGLT2 inhibitors in older adults: overcoming the age barrier","volume":"4","author":"Bellary","year":"2023","journal-title":"Lancet Healthy Longev"},{"issue":"10254","key":"10.1016\/j.amjcard.2025.08.028_bib0006","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.amjcard.2025.08.028_bib0007","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.amjcard.2025.08.028_bib0008","doi-asserted-by":"crossref","first-page":"JC51","DOI":"10.7326\/ACPJ202011170-051","article-title":"In heart failure, adding empagliflozin to medical therapy reduced a composite of CV death or HF hospitalization","volume":"173","author":"Palaskas","year":"2020","journal-title":"Ann Intern Med"},{"issue":"16","key":"10.1016\/j.amjcard.2025.08.028_bib0009","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.amjcard.2025.08.028_bib0010","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","volume":"77","author":"Maddox","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.amjcard.2025.08.028_bib0011","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"10.1016\/j.amjcard.2025.08.028_bib0012","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3390\/biomedicines12071507","article-title":"Impact of SGLT2 inhibitors on very elderly population with heart failure with reduce ejection fraction: real life data","volume":"12","author":"Balaguer Germ\u00e1n","year":"2024","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.amjcard.2025.08.028_bib0013","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afac201","article-title":"The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus","volume":"51","author":"Evans","year":"2022","journal-title":"Age Ageing"},{"issue":"4","key":"10.1016\/j.amjcard.2025.08.028_bib0014","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2666-7568(23)00032-6","article-title":"Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial","volume":"4","author":"Pratley","year":"2023","journal-title":"Lancet Healthy Longev"},{"issue":"2","key":"10.1016\/j.amjcard.2025.08.028_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101419","article-title":"Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit\/risk balance?","volume":"49","author":"Scheen","year":"2023","journal-title":"Diabetes Metab"},{"issue":"1","key":"10.1016\/j.amjcard.2025.08.028_bib0016","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jamacardio.2024.4489","article-title":"Early adoption of sodium-glucose cotransporter-2 inhibitor in patients hospitalized with heart failure with mildly reduced or preserved ejection fraction","volume":"10","author":"Abdel Jawad","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.amjcard.2025.08.028_bib0017","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s13670-024-00420-z","article-title":"Towards a prescription for change: interprofessional management of polypharmacy and deprescribing","volume":"13","author":"Perron","year":"2024","journal-title":"Curr Geriatr Rep"},{"issue":"3","key":"10.1016\/j.amjcard.2025.08.028_bib0018","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/jgs.14028","article-title":"Efficacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus: a pooled analysis","volume":"64","author":"Sinclair","year":"2016","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"10.1016\/j.amjcard.2025.08.028_bib0019","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1053\/j.ajkd.2021.09.015","article-title":"SGLT2 inhibitors and the risk of acute kidney injury in older adults with type 2 diabetes","volume":"79","author":"Zhuo","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.amjcard.2025.08.028_bib0020","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/M21-4776","article-title":"Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: a post hoc analysis of the DAPA-HF trial","volume":"175","author":"Butt","year":"2022","journal-title":"Ann Intern Med"},{"issue":"16","key":"10.1016\/j.amjcard.2025.08.028_bib0021","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1161\/CIRCULATIONAHA.122.061754","article-title":"Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial","volume":"146","author":"Butt","year":"2022","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.amjcard.2025.08.028_bib0022","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1161\/CIRCULATIONAHA.118.033810","article-title":"Long-term benefit of empagliflozin on life expectancy in patients with type 2 diabetes mellitus and established cardiovascular disease","volume":"138","author":"Claggett","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.amjcard.2025.08.028_bib0023","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.cardfail.2024.10.288","article-title":"Underutilization And sex disparities in real world heart failure guideline directed therapy prescription rates over time in a large health system","volume":"31","author":"Rasmusson","year":"2025","journal-title":"J Cardiac Fail"},{"issue":"11","key":"10.1016\/j.amjcard.2025.08.028_bib0024","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004402","article-title":"Contemporary epidemiology of heart failure in fee-for-service medicare beneficiaries across healthcare settings","volume":"10","author":"Khera","year":"2017","journal-title":"Circ Heart Fail"},{"issue":"12","key":"10.1016\/j.amjcard.2025.08.028_bib0025","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jacc.2020.07.044","article-title":"Sex-specific associations of cardiovascular risk factors and biomarkers with incident heart failure","volume":"76","author":"Suthahar","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.amjcard.2025.08.028_bib0026","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.cardfail.2023.10.320","article-title":"Sglt2 inhibitors in women and cardiovascular outcomes - meta-analysis of sex differences in eleven randomized clinical trials","volume":"30","author":"Shah","year":"2024","journal-title":"J Cardiac Fail"},{"issue":"7","key":"10.1016\/j.amjcard.2025.08.028_bib0027","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.119.043594","article-title":"Women's participation in cardiovascular clinical trials from 2010 to 2017","volume":"141","author":"Jin","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.amjcard.2025.08.028_bib0028","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/CIRCULATIONAHA.117.027551","article-title":"Trends in hospitalizations and survival of acute decompensated heart failure in four US communities (2005-2014): ARIC study community surveillance","volume":"138","author":"Chang","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2025.08.028_bib0029","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.15420\/cfr.2022.02","article-title":"Unequitable heart failure therapy for black, hispanic and american-indian patients","volume":"8","author":"Ilonze","year":"2022","journal-title":"Card Fail Rev"},{"issue":"2","key":"10.1016\/j.amjcard.2025.08.028_bib0030","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jchf.2022.08.023","article-title":"Treatment differences in medical therapy for heart failure with reduced ejection fraction between sociodemographic groups","volume":"11","author":"Witting","year":"2023","journal-title":"JACC Heart Fail"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914925004874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914925004874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T01:54:35Z","timestamp":1763171675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914925004874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":30,"alternative-id":["S0002914925004874"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2025.08.028","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of Sodium Glucose Co-Transporter-2 Inhibitor Utilization in Elderly Heart Failure Patients: A Real-World Population-Level Dataset Analysis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2025.08.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}